Shanghai Haoyuan Chemexpress Co.Ltd(688131) : the proposed acquisition of 100% equity of drug source drugs will be suspended from the 21st

Shanghai Haoyuan Chemexpress Co.Ltd(688131) (688131) announced on February 18 that the company plans to acquire 100% equity of YaoYuan Pharmaceutical Chemistry (Shanghai) Co., Ltd. (hereinafter referred to as “YaoYuan medicine”) from Wang Yuan and Shanghai Yuanmeng enterprise management consulting partnership by issuing shares and paying cash, and plans to issue shares to the controlling shareholders of the company to raise supporting funds of no more than 50 million yuan. The trading of the company’s shares has been suspended since February 21, and it is expected that the suspension will not exceed 10 trading days.